Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...2930313233343536373839...5960»
  • ||||||||||  Clinical, Journal:  First-generation somatostatin receptor ligands and pregnancy: lesson from women with acromegaly. (Pubmed Central) -  Jun 22, 2021   
    The number of pregnancies is still low and more data are necessary to conclude on the total safety of this treatment during gestation. In the meantime, based on the nonthreatening data from this review of literature, SRL treatment can be continued and/or reintroduced during pregnancy if necessary (mainly for persistent headaches) in women with acromegaly.
  • ||||||||||  Clinical, Review, Journal:  The Epidemiology of Pituitary Adenomas. (Pubmed Central) -  Jun 22, 2021   
    Most new cases diagnosed are prolactinomas and nonsecreting pituitary adenomas. Most clinically relevant pituitary adenomas occur in females, but pituitary adenomas are clinically heterogeneous.
  • ||||||||||  Review, Journal:  Update on the Genetics of Pituitary Tumors. (Pubmed Central) -  Jun 22, 2021   
    Exploring the genetic background of pituitary neuroendocrine tumors can lead to early diagnosis associated with better outcomes, and their molecular mechanisms should lead to novel targeted therapies even for sporadic tumors. This article summarizes the genes and the syndromes associated with pituitary tumors.
  • ||||||||||  bromocriptine / Generic mfg.
    Review, Journal:  The Role of Dopamine Agonists in Pituitary Adenomas. (Pubmed Central) -  Jun 22, 2021   
    A trial of cabergoline monotherapy can be effective in patients with biochemically mild acromegaly. Cabergoline combination with somatostatin receptor ligands or pegvisomant improves insulin-like growth factor level 1 in majority of patients.
  • ||||||||||  Review, Journal:  Acromegaly: Update on Management and Long-Term Morbidities. (Pubmed Central) -  Jun 22, 2021   
    We provide an update of acromegaly management with current recommendations. We also address long-term comorbidities emphasizing the changing face of the disease in more recent series, with a decrease of cardiovascular disease severity and an increased awareness of comorbidities like bone disease, manifested mainly as vertebral fractures and the change in the main cause of death (from cardiovascular disease to cancer in more recent series).
  • ||||||||||  Review, Journal:  Pituitary Tumors Centers of Excellence. (Pubmed Central) -  Jun 22, 2021   
    That core needs to be supported by experts from different disciplines such as neuroradiology, neuropathology, radiation oncology, neuro-ophthalmology, otorhinolaryngology, and trained nursing. To provide high-level medical care to patients with pituitary tumors, PTCOEs further pituitary science through research publication, presentation of results at meetings, and performing clinical trials.
  • ||||||||||  Journal:  A follow-up study on outcomes of endoscopic transsphenoidal approach for acromegaly. (Pubmed Central) -  Jun 22, 2021   
    The improvement in surgical remission rate support a positive surgical volume - remission rate relationship for acromegaly in the era of endoscopic endonasal skull base approaches. One possible factor for better results may be the increasing surgical experience in EETSA, which follows a trend toward gradual improvement of long-term late remissions via a multidisciplinary approach.
  • ||||||||||  Journal:  Acromegaly and Diabetes - A Hand in Glove Combination. (Pubmed Central) -  Jun 22, 2021   
    One possible factor for better results may be the increasing surgical experience in EETSA, which follows a trend toward gradual improvement of long-term late remissions via a multidisciplinary approach. No abstract available
  • ||||||||||  Journal:  PET-guided repeat transsphenoidal surgery for previously deemed unresectable lateral disease in acromegaly. (Pubmed Central) -  Jun 16, 2021   
    Finally, PA classification based on transcription factor expression (Pit-1, Tpit, and SF-1), as proposed by the 2017 WHO classification of pituitary tumors, may avoid the limitations of PA classification based solely on digital immunohistochemical detection of hormones. This study provides proof of concept that Met-PET/MRCR can be helpful in the evaluation of residual lateral sellar/parasellar disease in persistent acromegaly and facilitate targeted revision TSS in a subgroup of patients.
  • ||||||||||  Journal:  Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality? (Pubmed Central) -  Jun 12, 2021   
    Assessment of current and novel predictors of responsiveness to distinct therapy can lead to multilevel categorization of patients, allowing integration into new clinical guidelines and reduction of increased morbidity and mortality associated with acromegaly. This review compares current data from epidemiological studies and assesses the present-day application of prognostic factors in medical practice, the reality of precision therapy, as well as its future prospects in acromegaly, with a special focus on its relevance to the South Korean population.
  • ||||||||||  temozolomide / Generic mfg.
    [VIRTUAL] Diagnosis and management of a child with pituitary adenoma () -  Jun 9, 2021 - Abstract #ESPE2021ESPE_24;    
    Experimental medical therapy, e.g. temozolomide, is indicated in few pediatric patients with an aggressive or malignant pituitary tumour, and we need O6-methylguanine-DNA methyl transferase (MGMT) status for the clinical decision making. Close collaboration between the pediatrician and endocrinologist is very fruitful during transition to adulthood.
  • ||||||||||  Journal:  Discovery of nonpeptide 3,4-dihydroquinazoline-4-carboxamides as potent and selective sst2 agonists. (Pubmed Central) -  Jun 9, 2021   
    This class of molecules exhibits excellent human sst2 potency and selectivity against sst1, sst3, sst4 and sst5 receptors. Leading compound 3-(3-chloro-5-methylphenyl)-6-(3-fluoro-2-hydroxyphenyl)-N,7-dimethyl-N-{[(2S)-pyrrolidin-2-yl]methyl}-3,4-dihydroquinazoline-4-carboxamide (28) showed no inhibition of major CYP450 enzymes (2C9, 2C19, 2D6 and 3A4) and weak inhibition of the hERG channel.
  • ||||||||||  [VIRTUAL] Final Histopathologic Diagnoses of Preoperatively Diagnosed Pituitary Macroadenomas (Virtual Poster Gallery) -  Jun 8, 2021 - Abstract #AANP2021AANP_167;    
    This review emphasizes the fact that a small proportion of patients with sellar lesions receiving clinicoradiographic diagnoses of pituitary adenoma will in fact harbor alternate histologic findings, including a variety of neoplastic and non-neoplastic lesions. Surgical sampling yielding normal pituitary tissue may well be contributing to some of this discordance.
  • ||||||||||  [VIRTUAL] Resistant Hypertension in Acromegaly () -  Jun 7, 2021 - Abstract #AACE2021AACE_530;    
    Acromegaly is a rare pituitary disorder with high rates of concomitant hypertension. Therapy of acromegaly and its related clinical manifestations improve long-term cardiovascular outcomes.
  • ||||||||||  [VIRTUAL] Prognostic Factors in Acromegaly () -  Jun 7, 2021 - Abstract #AACE2021AACE_511;    
    Immunohistochemical staining is an important parameter in predicting the behavior of pituitary adenomas (Pas), especially through anterior pituitary hormones, but also through transcription factors. These, along with the clinical and biochemical characteristics of the patients can be integrated in a risk stratification system, which helps the therapeutic management.
  • ||||||||||  [VIRTUAL] Correlation of Acromegaly Musculosceletal Complications Development with Gender, Age of Patients and Term of Disease () -  Jun 7, 2021 - Abstract #AACE2021AACE_334;    
    We report a case of DKA as the event that led to the diagnosis of acromegaly. Acromegaly is a rare chronic disease caused by hypersecretion of growth hormone and characterized by excessive tissue growth leading to significant burden of complications and associate pathologies such as cardiovascular, musculoskeletal, respiratory, endocrine, and metabolic diseases.The objective of our research was to study interrelation of acromegaly musculoskeletal complications development dependent on age, gender of patients, and the duration of the disease.
  • ||||||||||  Clinical, Journal:  Clinical and Molecular Update on Genetic Causes of Pituitary Adenomas. (Pubmed Central) -  Jun 5, 2021   
    The genetic etiologies of a significant proportions of sporadic corticotropinomas have recently been identified with the discovery of USP8 and USP48 mutations. The elucidation of genetic and molecular pathophysiology in pituitary adenomas is a key factor for better patient management and effective follow-up.
  • ||||||||||  Retrospective data, Journal:  Clinical features and therapeutic outcomes of patients with acromegaly in Saudi Arabia: a retrospective analysis. (Pubmed Central) -  Jun 5, 2021   
    The elucidation of genetic and molecular pathophysiology in pituitary adenomas is a key factor for better patient management and effective follow-up. Our findings highlight the need for a national acromegaly registry to enable early identification, evaluation, and selection of the best therapeutic approaches to improve the outcome and remission rate of the disease.
  • ||||||||||  Journal:  Editorial: Health-Related Complications of Acromegaly. (Pubmed Central) -  Jun 4, 2021   
    This approach might be beneficial for the early detection of acromegalic patients and timely consultation to improve their outcomes. No abstract available
  • ||||||||||  Review, Journal:  Growth Hormone Receptor Regulation in Cancer and Chronic Diseases. (Pubmed Central) -  Jun 4, 2021   
    Loss of their function increases the GH-induced signaling in favor of aging and certain chronic diseases, exemplified by increased lung cancer risk in case of a mutation in the SOCS2-GHR interaction site. Insight in their roles in GHR signaling can be applied for cancer and other therapeutic strategies.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Clinical, Journal:  Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes. (Pubmed Central) -  Jun 4, 2021   
    Surgical cure of acromegaly is associated with improvement in blood pressure levels, however little is known about the effect of pegvisomant (PEGV) treatment in patients with hypertension...Hypertension is common in patients with acromegaly and significantly increases mortality, especially when there is concomitant CVD. These data suggest that treatment goals should extend beyond IGF-I normalization, and include optimisation of substitution of pituitary deficiencies and scrutinous screening and treatment of CVD.
  • ||||||||||  Review, Journal:  Genetic and Epigenetic Causes of Pituitary Adenomas. (Pubmed Central) -  Jun 4, 2021   
    Moreover, the deubiquitinase gene USP8, USP48, and BRAF mutations are associated with adrenocorticotropic hormone production. In this review, we describe the genetic and epigenetic landscape of PAs and summarize novel insights into the regulation of pituitary tumorigenesis.